Science and Research

Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin

Lung cancer is the leading cause of death of all cancer entities and small-cell lung cancer (SCLC) is the most malignant subtype. Despite good initial response to chemotherapy, many patients relapse early and success of second line treatment remains poor. For years, no relevant improvement of second line treatment has been achieved in the field of SCLC. Lurbinectedin, a novel RNA-polymerase II inhibitor has shown promising results in pretreated SCLC patients as single agent and in combination with other chemotherapeutic drugs leading to an orphan drug designation from the FDA. This article reviews the current data on this emerging substance and its impact on the treatment of SCLC.

  • Kauffmann-Guerrero, D.
  • Huber, R. M.

Keywords

  • Sclc
  • chemotherapy
  • lurbinectedin
  • orphan drug
  • fees from BMS Germany, personal fees from Bayer, personal fees from Boehringer
  • Ingelheim Germany, personal fees from Lilly Germany, personal fees from MSD
  • Germany, personal fees from Novartis Germany, personal fees from Pfizer Germany,
  • personal fees from Roche Germany, and personal fees from Takeda, outside the
  • submitted work. The authors report no other conflicts of interest in this work.
Publication details
DOI: 10.2147/LCTT.S239223
Journal: Lung Cancer (Auckl)
Pages: 27-31 
Work Type: Review
Location: CPC-M
Disease Area: LC
Partner / Member: LMU
Access-Number: 32184690
See publication on PubMed

DZL Engagements

chevron-down